---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006132"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:39:24.051440+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharmaceuticals appoints Yong Ben, M.D., MBA to Board of Directors

## Summary
- Dr. Ben appointed to board effective March 1, 2023; press release issued March 6, 2023.
- He brings over 20 years of oncology drug development experience, including roles at BeiGene, BioAtla, and AstraZeneca.
- Initial option grant of 5,307 shares; annual cash retainer of $40,000 and annual stock option grant.
- Company also entered into standard indemnification agreement with Dr. Ben.
- Appointment supports Corbus' precision oncology pipeline including CRB-701 and CRB-601.

## SEC filing metadata
- accession: 0000950170-23-006132
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/0000950170-23-006132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/crbp-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006132
- JSON: https://secwatch.observer/filing/0000950170-23-006132.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006132.txt

## Key facts
- Executive change
  Yong Ben was appointed as member of the Board at Corbus Pharmaceuticals Holdings, Inc..
  - Action: appointed
  - Role: member of the Board
  source text: On March 1, 2023, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Yong Ben, M.D., MBA, age 49, to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/0000950170-23-006132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.